VitaSpring Biomedical Co. Ltd. (VSBC) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
VitaSpring Biomedical Co. Ltd. (VSBC) trades at $0.0111 with AI Score 38/100 (Grade D). VitaSpring Biomedical Co. Ltd. is a biotechnology company focused on developing cell medicine drugs. Market cap: $2.30M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for VSBC: VSBC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VSBC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VSBC: 2/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
VitaSpring Biomedical Co. Ltd. (VSBC) Healthcare & Pipeline Overview
VitaSpring Biomedical Co. Ltd., a biotechnology firm specializing in cell medicine drug development, operates from its Irvine, California headquarters. Formerly Shemn Corp., the company focuses on innovative therapeutic solutions within the competitive healthcare landscape, facing challenges common to early-stage biotech ventures in the OTC market.
What Is the Investment Thesis for VSBC?
VitaSpring Biomedical Co. Ltd. presents a high-risk, high-reward investment opportunity, typical of early-stage biotechnology companies. The company's focus on cell medicine drug development positions it within a rapidly evolving and potentially lucrative market. However, the company's $2.30M market cap and negative P/E ratio of -0.55 reflect its current lack of profitability and reliance on future drug development success. Key value drivers include successful clinical trials, regulatory approvals, and strategic partnerships. Growth catalysts include advancements in cell medicine technology and increasing demand for innovative therapies. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. Investors should carefully consider the company's financial position, scientific progress, and market dynamics before investing.
Based on FMP financials and quantitative analysis
VSBC Key Highlights
VitaSpring Biomedical Co. Ltd. specializes in the development of cell medicine drugs, a high-growth area within biotechnology.
- The company was incorporated in 2016 and rebranded from Shemn Corp. in February 2020, marking a strategic shift.
- Headquartered in Irvine, California, a hub for biotechnology innovation.
- The company currently has a market capitalization of $2.30M, reflecting its early stage and developmental focus.
- The company's P/E ratio is -0.55, indicating that it is not currently profitable.
Who Are VSBC's Competitors?
VSBC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AURX Nuo Therapeutics, Inc. | $1.00 | +0.00% | $48.4M | 61 |
| IUGNF Imugene Limited | $0.09 | +9.17% | $43.8M | 41 |
| KNTPF Kintor Pharmaceutical Limited | $0.24 | +0.00% | $112M | 56 |
| MSCLF Satellos Bioscience Inc. | $6.25 | +11.81% | $96.6M | 52 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VSBC's Key Strengths?
Focus on innovative cell medicine therapies.
- Potential for high growth in a rapidly evolving market.
- Location in a biotechnology hub (Irvine, California).
What Are VSBC's Weaknesses?
Early-stage company with limited financial resources.
- Dependence on successful clinical trials and regulatory approvals.
- Lack of established revenue streams.
What Could Drive VSBC Stock Higher?
Clinical trial results for cell medicine drug candidates.
- Potential partnerships and collaborations with pharmaceutical companies.
- Regulatory submissions and approvals for new therapies.
What Are the Key Risks for VSBC?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures and regulatory setbacks.
- Competition from established pharmaceutical companies.
- Limited financial resources and reliance on future funding.
- OTC market risks, including low liquidity and potential for manipulation.
What Are the Growth Opportunities for VSBC?
- Advancements in Cell Therapy Technologies: The cell therapy market is experiencing rapid growth, driven by technological advancements and increasing clinical success. VitaSpring Biomedical can capitalize on this trend by developing innovative cell-based therapies for various diseases. The global cell therapy market is projected to reach $82.6 billion by 2030, offering significant growth potential for companies with promising cell therapy candidates. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Collaborating with leading research institutions and pharmaceutical companies can accelerate VitaSpring Biomedical's drug development efforts and expand its market reach. Strategic partnerships can provide access to funding, expertise, and distribution channels, enhancing the company's competitive position. The value of biotech partnerships is expected to continue to rise, with deals often exceeding hundreds of millions of dollars. Timeline: Ongoing.
- Expansion into New Therapeutic Areas: VitaSpring Biomedical can diversify its product pipeline by expanding into new therapeutic areas beyond its initial focus. Exploring opportunities in areas such as oncology, autoimmune diseases, and cardiovascular diseases can broaden the company's market potential and reduce its reliance on a single therapeutic area. The market for each of these therapeutic areas is substantial, representing multi-billion dollar opportunities. Timeline: 2-3 years.
- Securing Regulatory Approvals: Obtaining regulatory approvals from agencies such as the FDA and EMA is crucial for commercializing VitaSpring Biomedical's drug candidates. Successful clinical trials and regulatory submissions can unlock significant value for the company and pave the way for market entry. The approval of a novel cell therapy can generate hundreds of millions of dollars in annual revenue. Timeline: 3-5 years.
- Capitalizing on Orphan Drug Designations: Pursuing orphan drug designations for its cell medicine drugs can provide VitaSpring Biomedical with regulatory and financial incentives, including market exclusivity and tax credits. Orphan drug designations are granted to therapies targeting rare diseases, offering a faster and more streamlined regulatory pathway. The orphan drug market is growing rapidly, driven by increasing awareness of rare diseases and the availability of targeted therapies. Timeline: Ongoing.
What Are VSBC's Competitive Advantages?
- Proprietary cell medicine technologies and intellectual property.
- Expertise in cell-based therapy development.
- Potential for orphan drug designations and market exclusivity.
What Does VSBC Do?
VitaSpring Biomedical Co. Ltd., established in 2016 and headquartered in Irvine, California, is a biotechnology company dedicated to the development of cell medicine drugs. Originally incorporated as Shemn Corp., the company rebranded to VitaSpring Biomedical Co. Ltd. in February 2020, signaling a strategic shift towards its current focus. Cell medicine, also known as cell-based therapy, involves using living cells to repair or replace damaged tissues and organs, offering potential treatments for a wide range of diseases. VitaSpring Biomedical aims to innovate in this field, developing proprietary cell-based therapies. As a relatively young company, VitaSpring Biomedical is in the early stages of research and development, navigating the complex regulatory landscape and scientific challenges inherent in the biotechnology industry. The company's success hinges on its ability to develop effective and safe cell medicine drugs, secure regulatory approvals, and establish strategic partnerships to commercialize its products. The company trades on the OTC market, which presents both opportunities and challenges for investors.
What Products and Services Does VSBC Offer?
- Develops cell medicine drugs for various diseases.
- Conducts research and development in the field of cell-based therapies.
- Seeks to innovate in regenerative medicine.
- Aims to create proprietary cell-based treatments.
- Navigates the regulatory landscape for drug approval.
- Explores strategic partnerships for commercialization.
How Does VSBC Make Money?
- Focuses on research and development of cell medicine drugs.
- Aims to generate revenue through the commercialization of approved therapies.
- May seek partnerships and collaborations to fund development and expand market reach.
What Industry Does VSBC Operate In?
VitaSpring Biomedical operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. Key trends include personalized medicine, gene editing, and the development of novel biologics. VitaSpring Biomedical's focus on cell medicine aligns with the growing interest in regenerative medicine and cell-based therapies. Competitors include both large pharmaceutical companies and smaller biotech firms, such as AURX, GGBXF, IUGNF, KNTPF, and MSCLF, all vying for market share in this dynamic landscape.
Who Are VSBC's Key Customers?
- Patients suffering from diseases treatable with cell medicine.
- Healthcare providers seeking innovative therapeutic options.
- Potential pharmaceutical partners for licensing and collaboration agreements.
Company Profile
VitaSpring Biomedical Co. Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Riverside, US. The company is led by CEO Ssu-Chuan Lai. VSBC has traded publicly since 2019.
Financial Health
VitaSpring Biomedical Co. Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for VitaSpring Biomedical Co. Ltd. stands at 9.4%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is 0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -17.9%, the inverse of the P/E and a quick read on earnings relative to price.
VSBC Valuation & Market Position
With a $2.30M market cap, VitaSpring Biomedical Co. Ltd. sits in the micro-cap segment of the market. Relative to its peer group, VSBC's quantitative score of 38/100 is below the peer average of 56/100.
VSBC Financials
Bull Case vs Bear Case
Bull Case
- Focus on innovative cell medicine therapies.
- Potential for high growth in a rapidly evolving market.
- Location in a biotechnology hub (Irvine, California).
- Upcoming: Clinical trial results for cell medicine drug candidates.
Bear Case
- Early-stage company with limited financial resources.
- Dependence on successful clinical trials and regulatory approvals.
- Lack of established revenue streams.
- Potential: Clinical trial failures and regulatory setbacks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
VSBC Latest News
No recent news available for VSBC.
VSBC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VSBC.
Price Targets
Wall Street price target analysis for VSBC.
VSBC MoonshotScore
What does this score mean?
The MoonshotScore rates VSBC 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Ssu-Chuan Lai
CEO
Ssu-Chuan Lai serves as the Chief Executive Officer of VitaSpring Biomedical Co. Ltd. Details regarding Mr. Lai's prior experience and educational background are not available in the provided source data. As CEO, Mr. Lai is responsible for overseeing the company's strategic direction, research and development efforts, and overall operations. His leadership is crucial for navigating the challenges and opportunities in the biotechnology industry.
Track Record: Due to limited information, Ssu-Chuan Lai's specific achievements and milestones at VitaSpring Biomedical Co. Ltd. cannot be determined. The company's progress in developing cell medicine drugs and securing partnerships will be key indicators of his leadership effectiveness. The company's transition from Shemn Corp. to VitaSpring Biomedical Co. Ltd. occurred under his leadership.
VSBC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that VitaSpring Biomedical Co. Ltd. may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may have limited information available to investors, increasing the risk associated with investing in these securities. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, which can lead to greater price volatility and potential for fraud. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Lower trading volumes and wider bid-ask spreads.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Fewer regulatory protections compared to listed companies.
- Verify the company's registration and legal status.
- Obtain and review audited financial statements.
- Assess the company's management team and track record.
- Research the company's products and market potential.
- Understand the company's capital structure and ownership.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a qualified financial advisor.
- Company's incorporation and registration details.
- Physical headquarters in Irvine, California.
- Focus on cell medicine drug development.
- CEO Ssu-Chuan Lai's leadership.
- Company's transition from Shemn Corp.
VSBC Healthcare Stock FAQ
What does the AI Score mean for VSBC?
VSBC holds an AI Score of 38/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. VitaSpring Biomedical Co. Ltd. is a biotechnology company focused on developing cell medicine drugs. The company, formerly Shemn Corp., is based in Irvine, California.
What does VitaSpring Biomedical Co. Ltd. do?
VitaSpring Biomedical Co. Ltd. is a biotechnology company focused on the research, development, and potential commercialization of cell medicine drugs. These drugs aim to treat diseases by repairing or replacing damaged tissues and organs using living cells. The company operates primarily in the early stages of drug development, navigating the complex regulatory and scientific challenges inherent in the biotechnology industry.
What do analysts say about VSBC stock?
As of March 17, 2026, there is no available analyst coverage or consensus on VitaSpring Biomedical Co. Ltd. (VSBC) stock. The company's $2.30M market cap and OTC listing suggest limited institutional interest and research coverage. Investors should conduct their own independent analysis, considering the company's financial position, scientific progress, and market dynamics.
What are the main risks for VSBC?
VitaSpring Biomedical Co. Ltd. faces several significant risks inherent to its business and market position. As a biotechnology company focused on cell medicine, the primary risks revolve around the success of its drug development pipeline. Clinical trial failures, regulatory hurdles, and competition from larger pharmaceutical companies pose substantial threats.
What are the key factors to evaluate for VSBC?
VitaSpring Biomedical Co. Ltd. (VSBC) holds an AI score of 38/100 (low). presents a high-risk, high-reward investment opportunity, typical of early-stage biotechnology companies. Not financial advice.
How frequently does VSBC data refresh on this page?
VSBC's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VSBC's recent stock price performance?
VitaSpring Biomedical Co. Ltd. (VSBC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on innovative cell medicine therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VSBC overvalued or undervalued right now?
VitaSpring Biomedical Co. Ltd. (VSBC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VSBC before investing?
Before investing in VitaSpring Biomedical Co. Ltd. (VSBC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on VitaSpring Biomedical Co. Ltd.
- OTC market investments are inherently risky.